Hélio Pinczowski

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Fluconazole versus Amphotericin B in the treatment of Hematogenous Candidiasis: A matched cohort study

Elias Anaissie, S. E. Vartivarian, Dima Abi-Said et al. · The American Journal of Medicine · 1996 · 187 citations

Antifungal Agent, Health Sciences, Antifungal Agents +9

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

José Baselga, J. G. M. Segalla, Henri Roché et al. · Journal of Clinical Oncology · 2012 · 160 citations · Full text

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz et al. · European Journal of Cancer · 2021 · 67 citations · Full text

Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study

Felipe Melo Cruz, Daniel de Iracema Gomes Cubero, Patrícia Taranto et al. · Supportive Care in Cancer · 2011 · 53 citations

Medicine, Drug Resistance, Pharmacotherapy +4